Check out the latest published journal articles featuring interdisciplinary computational biology from the Long lab at Roswell Park.
Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer
- Journal: Cell Reports, December 2021
- Authors: Long MD, Jacobi JJ, Singh PK, Llimos G, Wani SA, Rowsam AM, Rosario SR, Hoogstraat M, Linder S, Kirk J, Affronti HC, Bergman A, Zwart W, Campbell MJ, Smiraglia DJ.
- Citation: doi: 10.1016/j.celrep.2021.110109. PMID: 34910907; PMCID: PMC8889623.
Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
- Journal: Nature Communications, October 2020
- Authors: Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI, Liu S, Ito F.
- Citation: doi: 10.1038/s41467-020-19192-z. PMID: 33110069; PMCID: PMC7592056.
Other recent publications
- Rosario SR, et al. JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy. Mol Cancer Res. 2023 Jan 3;21(1):24-35. doi: 10.1158/1541-7786.MCR-22-0316. PMID: 36166196; PMCID: PMC9808368.
- Yamashita N, et al. MUC1-C Dictates PBRM1-Mediate Chronic Induction of Interferon Signaling, DNA Damage Resistance and Immunosuppression in Triple-Negative Breast Cancer. Mol Cancer Res. 2022 Nov 29;. doi: 10.1158/1541-7786.MCR-22-0772. PMID: 36445328.
- Fushimi A, et al. Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer. Mol Cancer Res. 2022 Sep 2;20(9):1379-1390. doi: 10.1158/1541-7786.MCR-22-0165. PMID: 35612556; PMCID: PMC9437561.
- Chaudhry K, et al. Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy. Cytotherapy. 2022 Aug;24(8):802-817. doi: 10.1016/j.jcyt.2022.04.001. Epub 2022 May 17. PMID: 35589475.
- Yamashita N, et al. Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer. Cancers (Basel). 2022 May 24;14(11). doi: 10.3390/cancers14112580. PMID: 35681561; PMCID: PMC9179855.
- Kumar H, et al. Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. Front Oncol. 2022;12:842200. doi: 10.3389/fonc.2022.842200. eCollection 2022. PMID: 35646666; PMCID: PMC9130773.
- Zhu Q, et al. Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers. Cancers (Basel). 2022 May 10;14(10). doi: 10.3390/cancers14102350. PMID: 35625955; PMCID: PMC9139302.
- Bhattacharya A, et al. MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells. Mol Cancer Res. 2022 Apr 1;20(4):556-567. doi: 10.1158/1541-7786.MCR-21-0672. PMID: 35022313; PMCID: PMC8983489.
- He X, et al. An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity. Cancer Immunol Res. 2022 Mar 1;10(3):314-326. doi: 10.1158/2326-6066.CIR-21-0332. PMID: 34992135; PMCID: PMC8898291.
- Hagiwara M, et al. MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Oncoimmunology. 2022;11(1):2029298. doi: 10.1080/2162402X.2022.2029298. eCollection 2022. PMID: 35127252; PMCID: PMC8812775.
- Makino K, et al. Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling. J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003827. PMID: 35101945; PMCID: PMC8804689.
More first-author publications
- Long MD, et al. Dynamic patterns of DNA methylation in the normal prostate epithelial differentiation program are targets of aberrant methylation in prostate cancer. Sci Rep. 2021 Jun 1;11(1):11405. doi: 10.1038/s41598-021-91037-1. PMID: 34075163; PMCID: PMC8169877.
- Long MD, et al. The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression. Oncogene. 2019 Jan;38(3):421-444. doi: 10.1038/s41388-018-0450-6. Epub 2018 Aug 17. PMID: 30120411; PMCID: PMC6336686.
- Long MD, et al. Integrative genomic approaches to dissect clinically-significant relationships between the VDR cistrome and gene expression in primary colon cancer. J Steroid Biochem Mol Biol. 2017 Oct;173:130-138. doi: 10.1016/j.jsbmb.2016.12.013. Epub 2016 Dec 24. PMID: 28027912.
- Long MD, et al. The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer. Biomolecules. 2017 Feb 14;7(1). doi: 10.3390/biom7010015. Review. PMID: 28216563; PMCID: PMC5372727.
- Long MD, et al. Pan-cancer analyses of the nuclear receptor superfamily. Nucl Receptor Res. 2015 Dec;2. doi: 10.11131/2015/101182. Epub 2015 Dec 15. PMID: 27200367; PMCID: PMC4869537.
- Long MD, et al. Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. Nucleic Acids Res. 2015 Sep 3;43(15):7330-48. doi: 10.1093/nar/gkv642. Epub 2015 Jun 27. PMID: 26117541; PMCID: PMC4551916.
- Long MD, et al. Vitamin D receptor and RXR in the post-genomic era. J Cell Physiol. 2015 Apr;230(4):758-66. doi: 10.1002/jcp.24847. Review. PMID: 25335912; PMCID: PMC4574486.
- Long MD, et al. Cooperative behavior of the nuclear receptor superfamily and its deregulation in prostate cancer. Carcinogenesis. 2014 Feb;35(2):262-71. doi: 10.1093/carcin/bgt334. Epub 2013 Oct 8. PMID: 24104552; PMCID: PMC3908747.
Connect with the Long Lab
Email: Mark.Long@RoswellPark.org
Phone: 716-845-2541
Department of Biostatistics and Bioinformatics
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263